GNS Healthcare Raises $23 Million Led by Cigna Ventures
GNS Healthcare (GNS), a leading precision medicine company, today announced a $23 million Series D fundraising round, led by Cigna Ventures, a strategic corporate venture capital partner and wholly owned indirect subsidiary of Cigna Corporation (NYSE: CI). Joining the Cigna Ventures-led funding round were Amgen Ventures, Celgene, Echo Health Ventures, Alexandria Venture Investments, as well as former Caesar’s CEO and Aetna Division President Gary Loveman.
“We are thrilled to have Cigna contribute to our next phase of growth,” said Colin Hill, Chairman, CEO and Co-Founder of GNS Healthcare. “As one of the largest and most forward-thinking global health services companies, Cigna is the perfect complement to our cadre of leading biopharma companies and health plan partners committed to improving patient outcomes through causal AI and the precision healthcare it enables.”
As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging artificial intelligence to solve healthcare’s most crucial problems. GNS’s causal AI technology transforms data streams into in silico patients that precisely match therapeutics, procedures and care management interventions to individuals to drive personalized clinical care and medicine and improve health outcomes. The latest funding round will enable Cigna and others to deliver on increasing consumer demand for personalization in new and more effective ways.
“Cigna is committed to improving the total health and well-being of our customers – and the personalized clinical care interventions that we expect GNS to facilitate will play a huge role in achieving those improvements,” said Tom Richards, Global Lead, Strategy & Business Development at Cigna. “GNS aligns with our vision and together we can super-charge our advanced analytics capabilities and provide even deeper, more predictable insights that will further enhance customer access to the highest quality treatment and care, in the preferred and appropriate place, at the right time.”
With this announcement, Cigna joins other leading carriers and health plans and GNS investors, including Cambia Health Solutions, Echo Health Ventures, Horizon Blue Cross of NJ and Heritage Provider Network, as well as leading biopharma companies, including Amgen Ventures, Celgene Corporation and Zambon Pharmaceuticals, and other investors Mitsui, GHO Capital, Alexandria Venture Investments, Fort Rock Capital and Gary Loveman.